Compare · BNTX vs INKT
BNTX vs INKT
Side-by-side comparison of BioNTech SE (BNTX) and MiNK Therapeutics Inc. (INKT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BNTX and INKT operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BNTX is the larger of the two at $21.49B, about 380.4x INKT ($56.5M).
- Over the past year, BNTX is down 21.6% and INKT is up 54.8% - INKT leads by 76.4 points.
- INKT has been more active in the news (12 items in the past 4 weeks vs 8 for BNTX).
- BNTX has more recent analyst coverage (25 ratings vs 8 for INKT).
- Company
- BioNTech SE
- MiNK Therapeutics Inc.
- Price
- $85.42-0.07%
- $11.38-4.25%
- Market cap
- $21.49B
- $56.5M
- 1M return
- -9.22%
- +0.80%
- 1Y return
- -21.60%
- +54.83%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2021
- News (4w)
- 8
- 12
- Recent ratings
- 25
- 8
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
MiNK Therapeutics Inc.
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate includes AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
Latest BNTX
- SEC Form 6-K filed by BioNTech SE
- The Multi-Billion-Dollar Search for Better Glioblastoma Treatments
- SEC Form 6-K filed by BioNTech SE
- Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
- BioNTech upgraded by UBS with a new price target
- Bernstein initiated coverage on BioNTech with a new price target
- SEC Form 6-K filed by BioNTech SE
- BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
- SEC Form 6-K filed by BioNTech SE
- BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026
Latest INKT
- Director Ryan Barbara sold $19,141 worth of shares (1,500 units at $12.76), decreasing direct ownership by 6% to 21,969 units (SEC Form 4)
- MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting
- Director Ryan Barbara was granted 3,063 shares, increasing direct ownership by 15% to 23,469 units (SEC Form 4)
- Director Holcomb John Bradley was granted 2,330 shares, increasing direct ownership by 207% to 3,458 units (SEC Form 4)
- Director Corvese Brian was granted 3,084 shares, increasing direct ownership by 6% to 53,137 units (SEC Form 4)
- Director Behner Peter was granted 2,804 shares, increasing direct ownership by 14% to 22,919 units (SEC Form 4)
- Director Wiinberg Ulf was granted 2,416 shares, increasing direct ownership by 12% to 22,650 units (SEC Form 4)
- A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company
- MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
- Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026